**Orderable - BRAF NCCO NGS**

**Turnaround Time:** 15 days

**Specimen:**

FFPE

**Collection Information:**

Send blocks to pathology lab for cutting

**Reference Ranges:**

See report

**Interpretive Comments:**

In patients with advanced malignant melanoma BRAF V600 mutations have been shown to be associated with clinical response to therapies targeting BRAF, such as vemurafenib. (PMID: 2235632) While clinical guidelines for BRAF mutational analysis are evolving, current available guidelines recommend routine testing for BRAF V600 mutations in metastatic melanoma.(PMID:24129426)

**Comments:**

Patient is outside CCO criteria for funded testing

**Storage and Shipment:**

Deliver to lab at room temperature.
NRAS and BRAF for colon cancer. This assay has been internally validated to meet >99% sensitivity and specificity for mutations that are at 5% mutant allele frequency in the assessed DNA sample. Rarely, mutations are detected at <5% mutant allele frequency and these are confirmed using alternate methodology, including real-time quantitative PCR.

**Test Schedule:**
As required, Monday to Friday 0800-1600 hours